Characteristics and Real-World Outcomes of Patients Treated with Fecal Microbiota, Live-jslm (RBL) for the Prevention of Recurrent Clostridioides difficile Infection
Abstract Introduction Recurrent Clostridioides difficile infection (rCDI) is common, with symptoms ranging from diarrhea to life-threatening sepsis. This study aimed to assess the real-world outcomes of patients with rCDI in the United States (US) who received fecal microbiota, live-jslm (RBL), the...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-03-01
|
| Series: | Infectious Diseases and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40121-025-01130-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850202678284517376 |
|---|---|
| author | Sahil Khanna Sanghyuk Seo Min Yang Viviana Garcia-Horton Yipeng Gao Hannah H. Kim Loren Ormenaj Amy Guo |
| author_facet | Sahil Khanna Sanghyuk Seo Min Yang Viviana Garcia-Horton Yipeng Gao Hannah H. Kim Loren Ormenaj Amy Guo |
| author_sort | Sahil Khanna |
| collection | DOAJ |
| description | Abstract Introduction Recurrent Clostridioides difficile infection (rCDI) is common, with symptoms ranging from diarrhea to life-threatening sepsis. This study aimed to assess the real-world outcomes of patients with rCDI in the United States (US) who received fecal microbiota, live-jslm (RBL), the first US Food and Drug Administration-approved microbiota-based therapy for the prevention of rCDI after antibiotic treatment. Methods Adults with rCDI who received RBL between July 2023 and August 2024 at home or in a clinic and had ≥ 8 weeks of follow-up or experienced CDI recurrence at any time after RBL administration were included. Treatment success, defined as no CDI recurrence within 8 weeks of RBL, was assessed overall and in subgroups stratified by age, number of prior CDI recurrences, duration of the antibiotic washout period, prior bezlotoxumab use, and RBL administration setting. Results Among 196 patients who received RBL, 176 had either ≥ 8 weeks of follow-up or had < 8 weeks of follow-up but experienced CDI recurrence during that period. The treatment success rate at 8 weeks was 83.0%. No significant differences were observed in treatment success rates among subgroups based on age (< 65 years old vs. ≥ 65 years old: 85.9% vs. 80.2%, p = 0.20), duration of the antibiotic washout period (24 h: 80.0%, 48 h: 84.5%, 72 h: 85.0%, p = 0.68), number of prior CDI recurrences (< 3 vs. ≥ 3: 82.5% vs. 83.1%, p = 0.60), or prior bezlotoxumab use (86.4% vs. 83.7%, p = 1.00). Patients receiving RBL at home had a higher treatment success rate compared to those receiving RBL in a clinic (87.3% vs. 62.5%, p < 0.01). Conclusions RBL was highly effective in preventing rCDI in a real-world setting, including at-home administration. The effectiveness was also observed among high-risk subgroups, such as patients ≥ 65 years old and those with ≥ 3 prior CDI recurrences. |
| format | Article |
| id | doaj-art-dddbdf50c4f444c2831b816c7ab924fc |
| institution | OA Journals |
| issn | 2193-8229 2193-6382 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Infectious Diseases and Therapy |
| spelling | doaj-art-dddbdf50c4f444c2831b816c7ab924fc2025-08-20T02:11:42ZengAdis, Springer HealthcareInfectious Diseases and Therapy2193-82292193-63822025-03-0114479380210.1007/s40121-025-01130-5Characteristics and Real-World Outcomes of Patients Treated with Fecal Microbiota, Live-jslm (RBL) for the Prevention of Recurrent Clostridioides difficile InfectionSahil Khanna0Sanghyuk Seo1Min Yang2Viviana Garcia-Horton3Yipeng Gao4Hannah H. Kim5Loren Ormenaj6Amy Guo7Mayo ClinicFerring Pharmaceuticals, Inc.Analysis Group, Inc.Analysis Group, Inc.Analysis Group, Inc.Analysis Group, Inc.Analysis Group, Inc.Ferring Pharmaceuticals, Inc.Abstract Introduction Recurrent Clostridioides difficile infection (rCDI) is common, with symptoms ranging from diarrhea to life-threatening sepsis. This study aimed to assess the real-world outcomes of patients with rCDI in the United States (US) who received fecal microbiota, live-jslm (RBL), the first US Food and Drug Administration-approved microbiota-based therapy for the prevention of rCDI after antibiotic treatment. Methods Adults with rCDI who received RBL between July 2023 and August 2024 at home or in a clinic and had ≥ 8 weeks of follow-up or experienced CDI recurrence at any time after RBL administration were included. Treatment success, defined as no CDI recurrence within 8 weeks of RBL, was assessed overall and in subgroups stratified by age, number of prior CDI recurrences, duration of the antibiotic washout period, prior bezlotoxumab use, and RBL administration setting. Results Among 196 patients who received RBL, 176 had either ≥ 8 weeks of follow-up or had < 8 weeks of follow-up but experienced CDI recurrence during that period. The treatment success rate at 8 weeks was 83.0%. No significant differences were observed in treatment success rates among subgroups based on age (< 65 years old vs. ≥ 65 years old: 85.9% vs. 80.2%, p = 0.20), duration of the antibiotic washout period (24 h: 80.0%, 48 h: 84.5%, 72 h: 85.0%, p = 0.68), number of prior CDI recurrences (< 3 vs. ≥ 3: 82.5% vs. 83.1%, p = 0.60), or prior bezlotoxumab use (86.4% vs. 83.7%, p = 1.00). Patients receiving RBL at home had a higher treatment success rate compared to those receiving RBL in a clinic (87.3% vs. 62.5%, p < 0.01). Conclusions RBL was highly effective in preventing rCDI in a real-world setting, including at-home administration. The effectiveness was also observed among high-risk subgroups, such as patients ≥ 65 years old and those with ≥ 3 prior CDI recurrences.https://doi.org/10.1007/s40121-025-01130-5Fecal microbiota live-jslmRBLRecurrent Clostridioides difficile infection |
| spellingShingle | Sahil Khanna Sanghyuk Seo Min Yang Viviana Garcia-Horton Yipeng Gao Hannah H. Kim Loren Ormenaj Amy Guo Characteristics and Real-World Outcomes of Patients Treated with Fecal Microbiota, Live-jslm (RBL) for the Prevention of Recurrent Clostridioides difficile Infection Infectious Diseases and Therapy Fecal microbiota live-jslm RBL Recurrent Clostridioides difficile infection |
| title | Characteristics and Real-World Outcomes of Patients Treated with Fecal Microbiota, Live-jslm (RBL) for the Prevention of Recurrent Clostridioides difficile Infection |
| title_full | Characteristics and Real-World Outcomes of Patients Treated with Fecal Microbiota, Live-jslm (RBL) for the Prevention of Recurrent Clostridioides difficile Infection |
| title_fullStr | Characteristics and Real-World Outcomes of Patients Treated with Fecal Microbiota, Live-jslm (RBL) for the Prevention of Recurrent Clostridioides difficile Infection |
| title_full_unstemmed | Characteristics and Real-World Outcomes of Patients Treated with Fecal Microbiota, Live-jslm (RBL) for the Prevention of Recurrent Clostridioides difficile Infection |
| title_short | Characteristics and Real-World Outcomes of Patients Treated with Fecal Microbiota, Live-jslm (RBL) for the Prevention of Recurrent Clostridioides difficile Infection |
| title_sort | characteristics and real world outcomes of patients treated with fecal microbiota live jslm rbl for the prevention of recurrent clostridioides difficile infection |
| topic | Fecal microbiota live-jslm RBL Recurrent Clostridioides difficile infection |
| url | https://doi.org/10.1007/s40121-025-01130-5 |
| work_keys_str_mv | AT sahilkhanna characteristicsandrealworldoutcomesofpatientstreatedwithfecalmicrobiotalivejslmrblforthepreventionofrecurrentclostridioidesdifficileinfection AT sanghyukseo characteristicsandrealworldoutcomesofpatientstreatedwithfecalmicrobiotalivejslmrblforthepreventionofrecurrentclostridioidesdifficileinfection AT minyang characteristicsandrealworldoutcomesofpatientstreatedwithfecalmicrobiotalivejslmrblforthepreventionofrecurrentclostridioidesdifficileinfection AT vivianagarciahorton characteristicsandrealworldoutcomesofpatientstreatedwithfecalmicrobiotalivejslmrblforthepreventionofrecurrentclostridioidesdifficileinfection AT yipenggao characteristicsandrealworldoutcomesofpatientstreatedwithfecalmicrobiotalivejslmrblforthepreventionofrecurrentclostridioidesdifficileinfection AT hannahhkim characteristicsandrealworldoutcomesofpatientstreatedwithfecalmicrobiotalivejslmrblforthepreventionofrecurrentclostridioidesdifficileinfection AT lorenormenaj characteristicsandrealworldoutcomesofpatientstreatedwithfecalmicrobiotalivejslmrblforthepreventionofrecurrentclostridioidesdifficileinfection AT amyguo characteristicsandrealworldoutcomesofpatientstreatedwithfecalmicrobiotalivejslmrblforthepreventionofrecurrentclostridioidesdifficileinfection |